Showing 2271-2280 of 2657 results for "".
- Novartis Announces FDA and EMA Filing Acceptances of Beovu for Patients with Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-and-ema-filing-acceptances-of-beovu-for-patients-with-diabetic-macular-edema/2480351/Novartis announced that the FDA has accepted the company’s supplemental biologics license application (BLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME).
- Stephen D. McLeod, MD, Selected as Next CEO of American Academy of Ophthalmologyhttps://modernod.com/news/stephen-d-mcleod-md-selected-as-next-ceo-of-american-academy-of-ophthalmology/2480346/The American Academy of Ophthalmology board of trustees announced the unanimous selection of Stephen D. McLeod, MD, 57, as the Academy’s next chief executive officer (CEO). Dr. McLeod currently is the Theresa M. and Wayne M. Caygill, M.D. Distinguished Professor and Chair, Department of Oph
- Study: 1 in 10 Americans Have Not Had An Eye Exam In Five Years Or Morehttps://modernod.com/news/study-1-in-10-americans-have-not-had-an-eye-exam-in-five-years-or-more/2480339/Most people are aware they need to look after their physical health, we’re often told to eat healthier and exercise more. But many of us neglect one key part of our body’s wellbeing: our eye health. With the pandemic affecting our lives, booking an eye exam or looking
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medicalhttps://modernod.com/news/eyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical/2480302/Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Terms of the deal w
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- Gemini Therapeutics Announces Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021https://modernod.com/news/gemini-therapeutics-announces-data-from-its-ongoing-phase-2a-study-of-gem103-at-euretina-2021/2479579/Gemini Therapeutics announced that Raj Maturi, MD, Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing phase 2a study at EURETINA 2021
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to